A Clinical Trial for Patients with Advanced Cancers

2024-515020-36-00 Phase I and Phase II (Integrated) - Other Ongoing, recruiting

Start 24 Feb 2025 · Status Ongoing, recruiting · 4 EU/EEA countries · 16 sites

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ongoing, recruiting
Participants planned 348
Countries 4
Sites 16

Advanced Solid tumour

Key facts

Sponsor
Corbus Pharmaceuticals Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20], Diseases [C] - Neoplasms [C04]
Trial duration
24 Feb 2025 → ongoing
Decision date (initial)
2025-01-29
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid tumour

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Corbus Pharmaceuticals Inc.

Sponsor organisation
Corbus Pharmaceuticals Inc.
Address
500 River Ridge Drive
City
Norwood
Postcode
02062-5045
Country
United States

Scientific contact point

Organisation
Corbus Pharmaceuticals Inc.
Contact name
Ian Hodgson

Public contact point

Organisation
Corbus Pharmaceuticals Inc.
Contact name
Ian Hodgson

Locations

4 EU/EEA countries · 16 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 32 4
Italy Ongoing, recruiting 32 4
Romania Ongoing, recruiting 32 4
Spain Ongoing, recruiting 32 4
Rest of world
Turkey, United States, United Kingdom
220

Investigational sites

France

4 sites · Ongoing, recruiting
Institut Gustave Roussy
Early Drug Development and Genitourinary Oncology Group, 114 Rue Edouard Vaillant, 94800, Villejuif
Institut De Cancerologie De L Ouest
Medical Oncology, Boulevard Jacques Monod, 44805, Saint-Herblain Cedex
Centre Hospitalier Universitaire De Poitiers
Medical Oncology, 2 Rue De La Miletrie, 86000, Poitiers
Institut Regional Du Cancer De Montpellier
Medical Oncology, 208 Avenue Des Apothicaires, 34298, Montpellier Cedex 5

Italy

4 sites · Ongoing, recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Oncology, Largo Francesco Vito 1, 00168, Rome
Careggi University Hospital
Oncology, Largo Giovanni Alessandro Brambilla 3, 50134, Florence
Centro Ricerche Cliniche Di Verona S.r.l.
Oncology, Piazzale Ludovico Antonio Scuro 10, 37134, Verona
Istituto Europeo Di Oncologia S.r.l.
Oncology, Via Giuseppe Ripamonti 435, 20141, Milan

Romania

4 sites · Ongoing, recruiting
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti
Oncology, Soseaua Fundeni 252, 022328, Bucharest
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca
Oncology, Strada Republicii 34-36, 400015, Cluj-Napoca
Centrul De Oncologie-Euroclinic S.R.L.
Oncology, Strada Conta Vasile 2, 700106, Iasi
Centrul De Oncologie SF Nectarie S.R.L.
Oncology, Strada Caracal Nr 109, 200542, Craiova

Spain

4 sites · Ongoing, recruiting
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario Y Politecnico La Fe
Oncology, Avenida Fernando Abril Martorell 106, 46026, Valencia
Hospital Quironsalud Barcelona
Oncology, Placa D'alfonso Comin 5-7, 08023, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-03-12 2025-04-23
Italy 2025-05-09 2025-05-12
Romania 2025-02-24 2025-03-13
Spain 2025-02-25 2025-03-18

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-19 Spain Acceptable
2025-01-27
2025-01-27
2 SUBSTANTIAL MODIFICATION SM-1 2025-02-11 Acceptable 2025-03-27
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-04-02 Acceptable 2025-04-02
4 SUBSTANTIAL MODIFICATION SM-2 2025-04-17 Spain Acceptable
2025-07-09
2025-07-10
5 SUBSTANTIAL MODIFICATION SM-3 2025-11-25 Spain Acceptable
2026-02-06
2026-02-10